Youngen Pipeline

Small nucleic acid drugs, especially small interfering RNA (siRNA) and antisense oligonucleotides (ASO), have shown great potential in gene silencing and the treatment of various diseases. By precisel...

Small nucleic acid drugs, especially siRNA and ASO, have become important therapeutic tools in the biomedical field. These drugs, through precise regulation of gene expression, have opened new pathway...

RNA interference (RNAi) is a natural gene-silencing mechanism triggered by double-stranded RNA (dsRNA) that can specifically inhibit the expression of target genes. Since Fire and Mello first discover...

Small nucleic acid drugs, as an emerging therapy, show many advantages compared to existing small molecule drugs and antibody drugs. Their development process is shorter, the therapeutic effects are s...

On September 8, 2025, Beijing Youngen Biotechnology Co., Ltd. (Youngen) attended the 1st anniversary event of Bayer Co.Lab in China. This "Celebrate for Innovations" themed event aimed to jo...

Recently, a patent titled "siRNA for Inhibiting APP Gene Expression, Its Conjugates, and Applications" by Beijing Youngen Biotechnology Co., Ltd., Ltd. has been officially authorized. This p...